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ABSTRACT 
The serotonin system has been implicated in major depression since the 1960s, mainly 
based on the serotonin enhancing properties of antidepressants. Positron emission 
tomography, PET, is the in vivo molecular imaging method with the best spatial 
resolution. There has been a gradual development of suitable radioligands for 
serotonergic targets since the mid-1990s, widening the scope of PET studies of the 
serotonin system. [
11
C]MADAM is an established radioligand selective for the 
serotonin transporter, and [
11
C]AZ10419369 is selective for the 5-HT1B receptor. 
 
The aim of this thesis was to study the serotonin system in major depressive disorder 
and the serotonergic effects of treatment with antidepressive medication or with 
psychotherapy. In order to understand the results with [
11
C]AZ10419369 better we 
examined the sensitivity of this radioligand to baseline serotonin levels. 
 
In study I we examined serotonin transporter occupancy with PET and [
11
C]MADAM 
in responders to treatment with seven different antidepressants in different doses. Two 
tricyclic antidepressants (TCAs) and four selective serotonin reuptake inhibitors 
(SSRIs) were examined. Mirtazapine was included as a serotonin transporter “dummy”. 
Serotonin transporter occupancy could be confirmed in vivo for all TCAs and SSRIs. 
There was no significant difference in serotonin transporter occupancy between the old 
antidepressants, TCAs, and the new, SSRIs. Mirtazapine did not occupy the serotonin 
transporter. The average serotonin transporter occupancy in SSRIs and TCAs was 67 
%, which was significantly lower than the 80 % serotonin transporter occupancy 
previously postulated important for SSRI effect.         
 
In study II we investigated the effect of internet-delivered cognitive behavioural 
therapy (CBT) for recurrent major depressive disorder on [
11
C]AZ10419369 binding. 
Ten patients with an ongoing and untreated major depressive episode finished the study 
according to protocol and were examined with PET and [
11
C]AZ10419369 before and 
after CBT. All patients responded to treatment. The binding potential, BPND, was 
reduced by 33 % in the dorsal brain stem, which included the raphe nuclei, from which 
the serotonergic neurons project. Since the 5-HT1B receptor acts inhibitory, a reduction 
of 5-HT1B receptor density in the raphe nuclei would in theory result in a general 
stimulation of the serotonin system.  There were no other significant changes in 
radioligand binding in the brain with CBT. 
 
In study III we wanted to compare [
11
C]AZ10419369 binding in patients with an 
ongoing and untreated major depressive episode within recurrent major depressive 
disorder with age- and sex matched controls. Ten patients and ten controls were 
examined with PET and [
11
C]AZ10419369. [
11
C]AZ10419369 binding was lower in 
the anterior cingulate cortex (25 % lower) and associated regions (20 % lower in the 
subgenual prefrontal cortex and 45 % lower in the hippocampus). The difference in the 
anterior cingulate cortex survived Bonferroni correction for multiple comparisons. The 
anterior cingulate cortex is an established part of the neurocircuitry of depression. 
There were no significant differences in the other examined brain regions.  
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In study IV we correlated [
11
C]AZ10419369 binding with concentrations of serotonin 
and its metabolite 5-Hydroxyindoleacetic Acid (5-HIAA) in the cerebrospinal fluid 
(CSF) at baseline in healthy subjects. Twelve healthy subjects without psychiatric 
history were first examined with PET and [
11
C]AZ10419369 and then with lumbar 
puncture for CSF analysis. The CSF concentrations of serotonin and 5-HIAA were 
determined with high performance liquid chromatography. There were no significant 
correlations between levels of serotonin and 5-HIAA in the CSF and [
11
C]AZ10419369 
binding in the whole brain, in the caudate nucleus or in the occipital cortex. Since 
correlations between CSF and brain concentrations of serotonin and 5-HIAA have been 
demonstrated, [
11
C]AZ10419369 binding at baseline likely reflects 5-HT1B receptor 
density. This has bearing for the interpretation of study II and III.   
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1 INTRODUCTION 
 
1.1 RATIONALE FOR THIS THESIS 
Major depression is a significant contributor to the global burden of disease, and likely 
the leading cause of disability in the industrialized world[1]. In most cases major 
depressive episodes are highly treatable, although merely half of the patients respond to 
a selective serotonin reuptake inhibitor (SSRI), the standard first line of treatment[2]. 
 
Despite accumulating knowledge, the pathophysiology of major depression remains 
largely elusive[3]. Secondary depressions following neurological diseases, such as 
stroke, multiple sclerosis, and Parkinson’s disease underscore the importance of the 
brain also in primary depression, the subject of this thesis. The serotonin system has 
been implicated in the treatment of depression since the 1960s, when it was discovered 
that tricyclic antidepressants blocked serotonin reuptake[4]. 
 
The advent of molecular imaging in the 1980s constituted a leap in the development of 
methods to explore the chemistry of the living brain[5]. The gradual evolution of 
radioligands binding to serotonergic targets has paved the way for imaging of the 
serotonin system in the brain[6, 7].  
 
The general aim of this thesis was to apply these neuroimaging tools for clinical studies 
of the serotonin system in major depression and its treatment. Paper I describes a 
[
11
C]MADAM PET study of 5-HTT occupancy in responders to treatment with first 
and second generation antidepressants. In paper II-III the 5-HT1B receptor selective 
radioligand [
11
C]AZ10419369 was used to measure 5-HT1B receptors in recurrent 
major depressive disorder, in relation to cognitive behavioural therapy (II) and in 
comparison with controls (III). Since sensitivity to pharmacologically induced 
endogenous serotonin release has been reported for [
11
C]AZ10419369, we assessed this 
radioligand’s sensitivity to basal serotonin levels, correlating binding potential with 
concentrations of serotonin and its metabolite 5-hydroxyindoleacetic acid (5-HIAA) in 
cerebrospinal fluid (CSF) (paper IV), in order to better understand the results from 
study II-III. 
 
1.2 MAJOR DEPRESSIVE DISORDER 
A debilitating condition of lowered mood with congruent symptoms was well described 
as early as in ancient Greece. The disorder was termed melancholia according to the 
prevailing humoral pathology paradigm of the time [8]. In addition to the symptoms 
related to depressed mood and anhedonia, vital symptoms, such as typically disturbed 
sleep or loss of appetite, are commonly a part of depression. In a group of depressed 
patients there are instead atypical symptoms such as hypersomnia and increase in 
appetite[9].  
 
Depression can be characterized as chronic or episodic according to the lapse of time of 
depressive symptoms. Depressive episodes can occur within different forms of bipolar 
disorder, with alternating periods of abnormally reduced and elevated mood, or within 
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major depressive disorder[8]. This thesis focuses entirely on major depressive disorder, 
a unipolar form of mood disorder.  
 
Major depression is partly a familial disorder, with estimated average heritability in the 
range of 31-42%[10]. The risk of developing depression is determined by interactions 
between genetic liability and life stress, elegantly demonstrated in a longitudinal study 
of different polymorphisms for the serotonin transporter gene and vulnerability for 
depression in relation to stressful life events[11]. Furthermore, in at least some 
subgroups of depressed patients there appears to be a kindling effect, where previous 
depressive episodes induce an increased vulnerability of relapsing into future 
depressions[12]. 
 
Depression may be a life-threatening condition. A dose-response relationship between 
depressive symptoms and risk of developing coronary heart disease has been 
reported[13]. Severe depression is one of the disorders associated with the highest risk 
of suicide[14].  
 
1.2.1 Defining depression 
Emil Kraepelin, one of the pioneers in modern psychiatry, emphasized the episodic 
nature of depression and in particular its risk of recurrence[8]. These features have been 
captured in the latest versions of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM). The fourth edition of this manual, DSM-IV, was used for diagnosing 
depression throughout this thesis, as it was the most validated diagnostic instrument at 
the time[9]. 
 
The third version of DSM (DSM-III) revolutionized psychiatry, providing criteria-
based and thereby more reliable diagnoses. The DSM-III definition of major depression 
is a slightly modified version of the so called Feighner criteria[15]. A major depressive 
episode is defined by a set of symptoms, requiring at least either depressed mood or 
loss of interest [16], during at least two weeks. The minimal duration is drastically 
shorter than the one month that Feighner suggested. The decreased demand of time 
with symptoms required for fulfillment of the depression diagnosis has been criticized 
for leading to a risk of false positives, erroneously labeling distressed people as 
depressed [17].  
 
Horwitz and Wakefield have also voiced what one of the most prominent collaborators 
in the DSM task force, Robert Spitzer, deemed as the most important criticism of the 
major depression criteria in DSM-III and IV: the loss of context, except for 
bereavement. Disproportionate lowering of mood is a key feature in major 
depression[3] and disregarding stressful life situations can result in mislabeling people 
who are sad during difficult times as depressed. A later version, DSM-5, has recently 
been released, omitting context entirely from the diagnostic criteria[18].    
 
Another issue with the DSM definition is its broadness. The criteria for a major 
depressive episode can be fulfilled in 1497 ways[19]. With this heterogeneity different 
kinds of conditions are likely included in the definition. DSM critics like Carrol have 
argued that the broad and inclusive DSM criteria for depression eclipses more 
 11 
 
endogenous forms of depression, implying that the DSM definition of depression is 
more reliable, but less valid[20, 21]. To partially compensate for this there are separate 
diagnosis codes in DSM for melancholic and psychotic depressions, variants where 
medical treatment is strongly indicated. The above difficulties in defining depression 
have hampered the pathophysiological research in depression, and ignited a call for 
endophenotypic markers beyond the established diagnostic criteria[22, 23].  
 
1.2.2 Epidemiology 
As late as in the end of the 1960s depression was considered a rare disorder[24], 
probably since only the more severe cases, the tip of the iceberg, were brought into 
attention. The introduction of antidepressive medications spurred WHO-conducted 
population surveys, where prevalence rates for depression surged, revealing more of the 
iceberg[25]. In the longitudinal Lundby study, the inhabitants of an entire community 
were interrogated and psychiatrically assessed, yielding estimated life time incidence 
rates for depression of 22.5% for men and 30.7 % for women[26]. Based on data from 
structured interviews in the National Comorbidity Survey Replication in the United 
States, the life-time risk for major depressive disorder was estimated to 16.2 %, while 
the 12-month prevalence was 6.6%[27].  Two later WHO surveys of the global burden 
of disease have ranked major depression as the fourth leading cause of disease burden 
in the world[28, 29]. Based on the magnitude of the contribution of mental disorders, in 
particular depressive disorders, to public health according to these surveys, Whiteford 
et al. argued that prevention and treatment of mental disorders should be a priority[1].  
 
1.2.3 Pathophysiology 
There are several challenges in the study of the pathophysiology of major depressive 
disorder, the main being the heterogeneity in the depressive phenotype and its etiology, 
confounding effects of medication and large variabilities in potential biomarkers[3, 30, 
31]. The contribution of neuroimaging to the understanding of the neurocircuitry of 
depression will be dealt with in separate sections of this thesis. The two major current 
hypotheses are the monoamine theory and the stress-related model, revolving around 
the hypothalamic-pituitary-adrenal(HPA)-axis. The monoamine theory has been 
credited to Schildkraut, who, based on the noradrenergic actions of currently available 
antidepressants (monoamine oxidase inhibitors and imipramine) hypothesized that 
depression might be due to deficiencies of monoamines, especially noradrenaline[32]. 
This emphasis was soon questioned, since adrenergic stimulants such as amphetamine 
lacked proper antidepressant effect[33]. Lapin and Oxenkrug instead formulated the 
serotonin hypothesis of depression[33], which remains the pathophysiological theory 
with the most supporting evidence[3], and which is described in more detail below. 
This thesis focuses on the role of the monoamine serotonin in depression and its 
treatment. In their article Lapin and Oxenkrug bridged the theory of serotonin 
deficiency in the brain with involvement also of the HPA-axis, in terms of increased 
blood-corticosteroid levels in depression resulting in reduced serotonin levels in the 
brain[33]. 
 
There is a clear association between stressful life events and depression[34]. The HPA-
axis is activated by stressful stimuli[35]. This stress response has been implicated in 
major depression in a number of ways. Firstly, higher cortisol levels have been reported 
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in depressed subjects compared with controls[36]. This is in line with the increased risk 
of depression for patients with Cushing’s syndrome, in essence a hypercortisolistic 
state[37]. Furthermore, lower corticotrophin-releasing receptor messenger RNA has 
been found in the frontal lobes in a post mortem-study of depressed suicide victims[38]. 
Finally, there is a vast literature regarding a blunted plasma cortisol response to 
corticosteroid administration, commonly referred to as an abnormal dexamethasone 
suppression test[39]. The sensitivity of the dexamethasone test in major depression is 
modest, albeit higher in severe forms of depression, with psychotic as well as 
melancholic features[40]. This has led Fink and Taylor to include an abnormal response 
to dexamethasone as a diagnostic criterion in melancholia, a condition corresponding to 
what was formerly referred to as endogenous depression[41]. The American Psychiatric 
Association task force concluded that an abnormal dexamethasone suppression test 
strongly suggests melancholia, if appropriate exclusion criteria have been applied. A 
negative dexamethasone suppression test is not very informative[39].   
 
1.2.3.1 The serotonin hypothesis 
Allegedly, Gaddum was the first scientist to report on the importance of serotonin for 
mental health 1954, based on its ability to antagonize the effects of the hallucinogenic 
compound Lysergic Acid Diethylamide (LSD)[42]. During this early era of 
psychopharmacology, the effects of the first tricyclic antidepressant imipramine was 
discovered[43], inducing a paradigm shift in the treatment of major depression. 
Carlsson and coworkers could show that the examined tricyclic antidepressants blocked 
serotonin reuptake in the brain[4]. This discovery, together with a potential 
antidepressive effect of the serotonin precursor tryptophan[44], was fundamental for 
the serotonin hypothesis of depression[33]. Clomipramine was one of the most popular 
tricyclic antidepressants and it stood out as the most serotonergic[4]. This spurred 
Arvid Carlsson into developing the first selective serotonin reuptake inhibitor, 
zimelidine, indeed showing antidepressive properties[45]. The development of the 
SSRIs based on the importance of serotonin is to be counted as one of the major 
success stories of rational drug development, in the otherwise serendipitous trail of 
psychopharmacological progress.  
 
The antihypertensive reserpine, derived from the root Rauwolfia serpentina, and used 
as a psychotrophic plant for centuries in Indian herblore, was soon after its introduction 
as a drug reported to have depression as a possible side effect[46]. The monoamine- 
depleting effects of this compound were later revealed, giving support for the theory 
that lack of monoamines, including serotonin contributed to depression. Although the 
depressogenic effect of reserpine has been questioned[47], the depletion model has 
contributed to the research on depression and its treatment. Most noteworthy is 
depletion of the serotonin precursor tryptophan, in experiments where subjects are 
deprived of dietary tryptophan. Tryptophan depletion has induced depressive symptoms 
in patients with a history of major depressive episodes and has been shown to predict 
the risk of relapse[48]. However, tryptophan depletion does not affect symptoms in 
subjects with an ongoing depression[49]. In a meta-analysis, Ruhé and coworkers 
concluded that decreased mood with tryptophan depletion demonstrates a vulnerability 
trait becoming depressed, although the depletion studies fail to show a causal relation 
between serotonin and depression[50]. There is, however, a distinct depressive effect of 
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tryptophan depletion in recently remitted patients treated with serotonergic 
medications[49]. 
 
The concept of a serotonergic depression has also been postulated based on low levels 
of the serotonin metabolite 5-HIAA in a subgroup of depressed patients[51]. Low 5-
HIAA in CSF was found in suicide attempters[52], and was later corroborated as a 
biomarker for suicidal behaviour[53, 54]. The low 5-HIAA levels initially found in 
depression later turned out to be an effect of confounding antidepressant medication, 
which reduce CSF concentrations of 5-HIAA[53]. 
 
Previously, serotonergic function could be assessed through the stimulation of prolactin 
release with the serotonin enhancing drug fenfluramine. With this neuroendocrine 
challenge test depressed patients have shown diminished fenfluramine-induced 
prolactin release compared to controls[55, 56]. The serotonergic function was not 
normalized with recovery from major depression[57], suggesting that the blunted 
prolactin response to fenfluramine is a vulnerability trait for depression, rather than a 
result of the depressive episode in itself[58]. 
 
To conclude, the hypothesis that depression is caused by a deficiency of brain serotonin 
has not been corroborated. However, there is abundant evidence for an involvement of 
serotonin in the pathophysiology of depression[59]. The crude version of the serotonin 
hypothesis still has had a major impact in explaining the phenomenon from which it 
was derived, namely the serotonin enhancement mediating the thymoleptic effect[33] 
of a majority of the current antidepressants[60-62]. 
  
1.2.4 Treatment 
There are three treatment modalities for major depression in common clinical practice: 
antidepressant medications, psychotherapy, and electroconvulsive therapy (ECT), the 
first two of which are described in more detail below. ECT is the most effective 
treatment option in daily routine care for major depressive episodes[63], with the 
relatively unique feature of better effect the more severe the depression[64]. The high 
remission rate with ECT for depression is to be weighed against the risks associated 
with general anesthesia and the risk of retrograde amnesia[65]. Therefore ECT is 
primarily reserved for the treatment of severe and/or treatment refractory major 
depression[66].  
 
1.2.4.1 Antidepressants 
Medications with antidepressive effects can be divided into five different categories 
based on the known mechanism of action: selective serotonin reuptake inhibitors 
(SSRI), selective noradrenaline reuptake inhibitors (NRI), nonselective monoamine 
reuptake inhibitors, monoamine oxidase inhibitors (MAOI) and other mechanisms of 
action.  
 
An SSRI is generally the first line of treatment, since it in most cases will be well 
tolerated[67]. The SSRI are generally considered effective for the treatment of 
depression, with insignificant differences in efficacy within the group[68]. The number 
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needed to treat has been reported to be 5, with the large placebo effect in mild to 
moderate depression potentially obscuring antidepressant treatment effetcts[69]. 
 
Reboxetine has been the NRI most frequently used in recent times. Its antidepressant 
effects has been questioned[70], which casts a shadow over inhibition of noradrenalin 
reuptake as a mechanism of action for antidepressants. Based on the combined 
noradrenergic and serotonergic effects of venlafaxine[71] and duloxetine [72], these 
drugs have been referred to as serotonin noradrenaline reuptake inhibitors (SNRI).This 
dual monoaminergic action is also shared by some of the tricyclic antidepressants, such 
as amitriptyline and clomipramine[71, 73]. Amitriptyline and clomipramine were 
reported to have greater efficacies than SSRIs in a meta-analysis of the treatment of 
hospitalized patients with depression[74]. These tricyclic antidepressants are not 
selectively targeting reuptake of serotonin and noradrenaline, their anticholinergic 
effects are also well known[75]. 
 
The monoamine oxidase inhibitors (MAOI) were contemporary with the tricyclic 
antidepressants. The first-generation MAOIs inhibited monoamine oxidase irreversibly 
and had a convincing antidepressive effect[76]. Their use has been reduced to a third or 
fourth line treatment for depression[77]  due to the risk of life-threatening hypertensive 
crisis when interacting with dietary tyramine[78]. Moclobemide, a reversible and 
selective monoamineoxidase-A inhibitor with an improved safety profile[79], has been 
developed and shown similar antidepressive efficacy as SSRI[80]  
 
Mirtazpine has a receptor-mediated monoaminergic action[81], and does not block 
serotonin reuptake[82], illustrating other mechanisms of action. The perhaps most 
intriguing finding recently in the progress of antidepressant development is the potent 
and fast antidepressive effect of the N-methyl-d-aspartate (NMDA) receptor antagonist 
ketamine, paving the way for new modes of action in the treatment of depression. 
 
1.2.4.2 Psychotherapy 
Several forms of psychotherapy have been found effective in the treatment of 
depression, although cognitive-behavioural therapy (CBT), interpersonal therapy and 
problem-solving therapy have the most robust evidence[83]. Cognitive behavioural 
therapy might have almost as good antidepressive effect as SSRIs[84]. However, the 
effects may have been overestimated due to publication bias[85]. Furthermore, many 
randomized controlled trials study the effect of CBT for the treatment of depression 
with waiting lists as control condition, for which there is virtually no anticipated 
positive effect [86]. To more accurately address the specific efficacy of CBT, 
psychotherapy should be compared with pharmacological treatment and a proper 
placebo group. 
 
In CBT for depression, the focus on modifying dysfunctional thoughts may vary in 
different schools and according to the therapist’s and patient’s preferences. In all forms 
of CBT the main goal with the treatment is to promote functional behaviours in the 
patient’s life context[87, 88]. With this rationale, in-session behaviour becomes 
secondary, and alternative treatment administration routes have been developed. 
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Internet-based CBT for depression has shown similar effects as clinician-administered 
treatment[89] and it has also been found effective in routine psychiatric care[90]. 
 
1.3 THE SEROTONIN SYSTEM 
Serotonin is an ancient transmitter substance, evolving from tryptophan possibly 3 
billion years ago[91]. Based on phylogenetical comparisons, the primordial 5-HT (5-
Hydroxytryptamine, chemical name for serotonin) receptors appeared in the world 700-
800 million years ago, which is before the dopaminergic and adrenergic receptor 
systems[91, 92]. The fundamental importance of serotonin is obvious from its 
widespread distribution, present in nearly all living organisms, and in humans in all the 
organs of the body[91]. Tryptophan can be synthesized in chloroplasts in plants. In 
animal cells this ability is lost, making animals dependent on dietary tryptophan for the 
synthesis of serotonin[93]. The resulting sparsity of serotonin in animals is believed to 
be one of the reasons for the development of a plethora of 5-HT receptors, in order to 
make the most out of the available serotonin[91]. The synthesis of serotonin is limited 
to certain cell types, neurons and mast cells in particular[91].  
 
Serotonin was initially characterized as a vasoconstrictor substance in serum[94], hence 
its name. Twarog and Page 1953 reported the presence of serotonin in the mammalian 
brain[95]. Soon after this discovery, serotonin was suggested as a transmitter substance 
in the brain[96]. Serotonin signaling is mediated through 14 structurally and 
pharmacologically distinct receptor subtypes[97]. With one exception, the ligand-gated 
ion channel termed 5-HT3 receptor, the 5-HT receptors couple to G-proteins, which 
transmit the signal into the cell upon serotonin binding to the receptors[97]. Serotonin 
levels are regulated extracellularly by reuptake via the serotonin transporter and 
intracellularly by degrading enzymes such as monoamine oxidase. 
 
Serotonin is involved in a variety of functions in the body, such as appetite 
regulation[98], learning and memory[99, 100], sleep[101], thermoregulation[102], pain 
control[103] and modulation of sexual behaviour[104]. There is a role for serotonin 
also in complex behaviours such as social positioning[105]. Improved mood and self-
confidence, even in the absence of a distinct major depressive episode, has been 
described in an early report from patients treated with SSRIs[106].  
 
The serotonin system is one of the main targets for psychotropic medications, with 
indications ranging from anxiety disorders and depression to premenstrual dysphoria. 
The importance of serotonin in major depression and its treatment is reviewed in 
1.2.3.1.  
 
1.3.1 Serotonergic pathways 
The anatomy of the serotonin system was initially mapped in the rat brain with 
histochemical fluorescence methods by Dahlström and Fuxe[107], who demonstrated 
that the cell bodies of serotonergic neurons were concentrated in the raphe nuclei in the 
brain stem. This general architecture, with serotonergic neurons projecting from raphe 
nuclei, is also found in humans[108, 109].  
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The serotonin system in mammalian brains can be divided into two distinct 
subdivisions: a rostral division, projecting from the midbrain and rostral pons to the 
forebrain, and a caudal division, with cell bodies in the medulla oblongata, with spinal 
projections[110]. The cell bodies of the rostral serotonergic neurons are mainly grouped 
into a dorsal and a median nucleus, with ascending projections. The dorsal raphe 
nucleus is located in the ventral part of the periaqueductal gray matter of the midbrain 
and contains the largest number of serotonergic neurons, around 165,000 in humans. 
The median raphe is the second largest cluster of serotonergic neurons in the brainstem, 
consisting of around 65,000 neurons, and it is mainly found in the rostral ponsis[110].  
 
The ascending serotonergic nerve fibers project diffusely to the brain, mainly from the 
dorsal and median raphe nuclei, with particularly dense innervations of layer IV in the 
visual cortex, the striatum, the hypothalamus, and parts of the thalamus[110] (figure 1). 
Morphologically the ascending serotonergic projections form a dual system, with either 
fine varicose axons originating from the dorsal raphe nucleus (D-fibers) or beaded 
axons arising from the median raphe nucleus (M-fibers). The two systems seem to 
coexist in most parts of the brain, with the cerebral cortex as an example of dual 
contribution to serotonergic innervation. However, the striatum is almost exclusively 
innervated by D-fibers and the hippocampus receives serotonergic input largely 
through M-fibers[110]. The functional importance of the dual system of ascending 
projections in the serotonin system is not yet fully elucidated, although the M-fiber 
system from the median raphe nucleus has been suggested to be of particular 
importance for depression, based on its innervation of the hippocampus and the limbic 
cortex[111].  
  
                                                        
 
Figure 1. Midline sagittal section of the brain, illustrating the raphe nuclei and their 
projections. 
  
1.3.2 5-HIAA and serotonin in cerebrospinal fluid 
Serotonin is metabolized by monoamineoxidase A and B into 5-HIAA, which can be 
measured in the CSF. CSF 5-HIAA is considered a good index of serotonin turnover in 
the central nervous system[112]. Serotonin is generally present in CSF in lower 
concentrations than 5-HIAA and therefore more difficult to detect[113]. Hence, its 
metabolite 5-HIAA has been more frequently used in studies of serotonergic activity, 
especially in the field of psychiatry[52, 53, 114]. With improved quantification 
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methods, measurement of serotonin concentrations in the CSF has resurfaced as a 
method to estimate extracellular serotonin in the brain[115, 116].  
 
A positive correlation between CSF and brain levels of serotonin has been shown in 
rodents[117]. In non-human primates a two-fold increase in serotonin concentration 
was demonstrated in the CSF after SSRI administration, and CSF serotonin was 
proposed as a useful index of central serotonin release[118]. In humans, a correlation 
between serotonin levels in the CSF and in the caudate nucleus in the brain was shown 
by Wester et al. [119] in a post mortem material. Likewise, correlations have been 
found between 5-HIAA and serotonin concentrations in the brain[120] and between 5-
HIAA in the brain and cerebrospinal fluid in the same subjects[119, 121]. 
 
The most non-invasive method for collection of samples from the CSF is by lumbar 
puncture (LP). With LP, contamination of the brain-derived CSF with serotonin and 5-
HIAA from the spinal cord is possible[122]. However, for 5-HIAA a rostral-caudal 
concentration gradient is well described[119, 121, 123-125], implying that the brain is 
the major contributor of CSF 5-HIAA.  
 
1.3.3 The serotonin transporter 
Extracellular serotonin levels are regulated by a selective Na
+
/Cl
- 
ATP-dependent 
transport protein, the 5-hydroxytryptamine transporter (5-HTT)[126]. 5-HTT is 
encoded by a single gene localized to chromosome 17q11.1-17q12 and is expressed on 
human neuronal, platelet, placental, and pulmonary membranes[127]. In neurons, the 
active serotonin transporters are located in the plasma membrane presynaptically[128]. 
 
Autoradiographical studies of the human brain have demonstrated the highest 5-HTT 
densities in the raphe nuclei[129, 130], medium densities in putamen, and lower levels 
in the frontal cortex post mortem[129-132]. Negligible 5-HTT binding was detected in 
the cerebellum[129-132]. This rank order of 5-HTT densities has been confirmed with 
PET and the serotonin transporter-specific radioligands [
11
C]DASB, [
11
C]MADAM 
and [
11
C](+)McN5652[133-135]. 
   
1.3.4 Serotonin receptor subtypes 
Serotonin binds to a wide repertoire of proteins, with 14 known 5-HT receptors[97] and 
20 5-HT receptor transcripts[91]. The 5-HT receptors can be structured into a 
dendrogram according to their amino acid sequences ([97], figure 2). All 5-HT 
receptors, except the 5-HT3 receptor, are seven-transmembrane-spanning, G protein- 
coupled receptors[97].  
 
Seven 5-HT receptor families have been identified[97] (figure 2). The 5-HT1 receptor 
family inhibits adenylate cyclase via Gi-proteins[97, 136]. All members of the 5-HT2 
receptor family mobilize intracellular calcium via phospholipase C. The 5-HT3 receptor 
is a ligand-gated ion channel. The 5-HT4, 5-HT5, 5-HT6, and 5-HT7 receptors all 
stimulate adenylate cyclase via Gs-proteins[137].   
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The 5-HT1 receptor family stands out among serotonin receptors for its distinctly 
inhibitory signal transduction properties. The regulatory function of 5-HT1 receptors in 
the serotonin system makes them especially interesting for studies of generalized 
conditions such as major depression.  
 
The 5-HT1A receptor is more studied, see 1.6. The 5-HT1A receptor is more frequent in 
rodents. However, based on the current molecular imaging database, 5-HT1B receptors 
are four times more frequent in the human brain[138].  
 
                                        
 
Figure 2. Dendrogram showing the evolutionary relationship between human 5-HT 
receptor protein sequences. The length of each branch corresponds to the evolutionary 
distance between the receptor subtypes. Reproduced from: Neuropharmacology, 
volume 38, N.M. Barnes and T. Sharp: A review of central 5-HT receptors and their 
function, pages 1083-1152, © 1999, with permission from Elsevier. 
 
1.3.4.1 The 5-HT1B receptor 
The 5-HT1B receptor was initially believed to be present only in rodents[139] and  the 
5-HT1D receptor was thought to be the human counterpart[97]. This fallacy confused 
the results of early 5-HT1B receptor studies. With the tools of molecular biology it has 
been made clear that 5-HT1B receptors are expressed in rodents[140] as well as 
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humans[141]. The receptor initially termed 5-HT1Dβ has hence been recognized as the 
human 5-HT1B receptor[97]. 
 
The gene encoding the 5-HT1B receptor in humans is located on chromosome 6[142]. 
The 5-HT1B receptor is a G protein-coupled seven-transmembrane-spanning receptor, 
negatively linked to adenylate cyclase [137]. In the brain, the 5-HT1B receptors act 
either as presynaptic autoreceptors or as postsynaptic heteroreceptors. Based on the 
reduced 5-HT levels with 5-HT1B receptor agonists, and the increased serotonin release 
with 5-HT1B receptor antagonists, the 5-HT1B autoreceptor seems to control the release 
of serotonin from the presynaptic bulb through inhibition[143]. The heteroreceptor 
function mediated via 5-HT1B receptors is serotonergic inhibition of non-serotonergic 
neurons. 5-HT1B receptors have been found postsynaptically mainly on neurons in the 
major pathways in the brain, GABA and glutamate, as well as on modulatory systems 
such as acetylcholine [144].   
 
The distribution of 5-HT1B receptors has been mapped with autoradiography[145].The 
highest 5-HT1B receptor densities were found in the substantia nigra and the globus 
pallidus. Intermediate 5-HT1B receptor binding was found in the striatum and in the 
neocortex, although there was a subregion of the medial occipital cortex with denser 
labeling. The 5-HT1B receptor levels were lower in the amygdala and in the 
hippocampus. In the cerebellar cortex the 5-HT1B receptor density was negligible. This 
rank order of 5-HT1B receptor distribution has been confirmed with PET and the 5-
HT1B receptor selective radioligand [
11
C]AZ10419369[146-148]. 
 
The functions of the 5-HT1B receptors can be extrapolated from studies with agonists 
and antagonists and animal models. 5-HT1B receptor mice are partially resilient to the 
appetite reducing effects of fenfluramine[144]. A 5-HT1B receptor agonist administered 
to rats decreased immobility time in the forced swimming test, corresponding to 
antidepressive effect in this animal model[149]. Impaired working memory has been 
reported in 5-HT1B receptor knockout mice [150]. The absence of 5-HT1B receptors has 
been reported to have behavioural consequences, with increased aggression [151] and 
exploratory behaviour [152], impulsivity, and addictive behaviour [153, 154]. 
Conversely, with overexpression of 5-HT1B receptors in the dorsal raphe nucleus 
animals became more vulnerable to stress [155]. 
 
In humans there are implications of an involvement of 5-HT1B receptors in the 
pathophysiology of depression. Differences of 5-HT1B mRNA expression between 
people who committed suicide and controls have been found, in a post-mortem 
material[156]. An association between a 5-HT1B receptor gene polymorphism and 
major depression has been found[157]. In the previous PET study on 5-HT1B receptors 
in MDD a lower binding in the ventral striatum/ventral pallidum in depressed subjects 
compared to controls was reported[158]. Treatment with 5-HT1B receptor antagonists as 
adjunctive to SSRIs has been suggested to increase efficacy and reduce time of onset of 
antidepressant action [159]. 
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1.4 POSITRON EMISSION TOMOGRAPHY 
The living brain was formerly thought inaccessible for examination due to the bony 
fortress of the skull. Ionizing radiation that passes through the cranium provides a 
means to study the brain. The term positron emission tomography describes the basic 
principle of the technique: sliced measurement of the emission of positrons. Positron 
emission is detected and projected into 2-D images (slices) through image 
reconstruction algorithms.  
 
PET radioligands are molecules with known binding sites, and which are labeled with 
positron(β+) emitting isotopes. The radioligand applied determines what can be 
measured in each PET experiment. The radionuclides most commonly used are 
11
C, 
13
N, 
15
O and 
18
F[160]. In this thesis carbon-11 radioligands are used throughout. 
11
C 
has a half life of approximately 20 minutes. The positron emitting radionuclides in 
general share a shortage of neutrons, which makes them unstable due to reduced ability 
to buffer the repelling forces of the nuclear protons. A proton is then converted to a 
neutron in the nucleus, while releasing a positron and an electron neutrino. The positron 
is the antiparticle of the electron.  
 
At PET the radioligand is typically injected intravenously. In brain PET, lipophilic 
radioligands are used to enable passage through the blood brain barrier (BBB). A small 
portion of the injected dose of radioligand enters the brain and binds to the target 
protein (figure 3). The radioligand emits a positron through β+ decay. After a short 
distance (the β+ range, typically 1 mm, depending on the isotope) the β+ interacts with 
its antiparticle the electron (β-). This encounter results in annihilation of the particle 
pair, transforming the conserved energy (1.02 MeV) into a photon pair (γ-particles). 
The photons are emitted in opposite directions at approximately 180°±0.25° and travel 
through tissue, skull and air before the coincidences are detected by the surrounding 
PET system. The divergence from the 180° route, the non-collinearity effect, depends 
on the isotope used, with its momentum of β+ and β- at annihilation[160]. The β+ range 
and the non-collinearity effect set the physical limitations to image resolution. The 
intensity of the γ-rays are attenuated by the passage through tissue and skull. To 
compensate for this a transmission scan normally precedes the acquisition of emission 
data, to enable individual attenuation correction. 
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Figure 3. Schematic picture of the principle of PET. The radioligand (pink circle) 
passes through the BBB and enters the brain (blue circle) where it binds to the target 
protein. A positron, β+, is emitted from the radioligand, encountering its antiparticle 
the electron, β-, within a few millimetres distance. The annihilation of this particle pair 
results in two gamma (γ) rays travelling at approximately 180 degrees from each other, 
detected by the PET system (black circle).  
 
The spatial resolution is the ability of the imaging system to separate objects that are 
located in close proximity to one another. It is expressed in terms of the full width at 
half maximum (FWHM) of the image representing an object. With the Gaussian 
representation of a perfect point source, FWHM is defined as the distance where the 
intensity in the image is half of the maximal value. In practice the image resolution is 
mainly determined by the PET system used: see chapter 3.3.  
 
1.5 PET RADIOLIGANDS FOR THE SEROTONIN SYSTEM 
The molecular diversity of the serotonin system has created a vast array of druggable 
targets for radioligand development. In the recent review by Zimmer and Le Bars, 13 
PET radioligands for 5-HT receptors tested in humans are counted, binding to 5-HT1A, 
5-HT1B, 5-HT2A, 5-HT4, or 5-HT6 receptors[7]. PET radioligands for imaging of the 5-
HT7 receptors are under development[161]. The most successful radioligands for the 5-
HTT are [
11
C]DASB(3-amino-4-(2-diethylamino-methyl-phenylsulfanyl)-benzonitrile) 
γ 
γ 
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and [
11
C]MADAM(N,N-dimethyl-2-(2-amino-4-methylphenylthio)benzylamine)[6]. In 
paper I [
11
C]MADAM was applied. In paper II-IV the 5-HT1B receptor selective 
radioligand [
11
C]AZ10419369 was used. 
 
1.5.1 Imaging the serotonin transporter 
The success story of antidepressant and anxiolytic drugs that inhibit 5-HT reuptake 
spurred the development of radioligands for imaging of serotonin transporters in the 
living human brain[6]. The first attempts to make tracers specific for 5-HTT were 
carbon-11 or fluorine-18 modifications of SSRIs. Despite displaying high affinity and 
selectivity for 5-HTT in vitro, the radiolabeled SSRIs have had questionable binding 
specificity in vivo, as well as slow binding kinetics[162]. 
 
The first 5-HTT selective PET radioligand  was the isoquinoline derivative 
[
11
C](+)McN5652 (trans-1,2,3,5,6,10-β-hexahydro-6-[4-(methylthio)phenyl]pyrrolo-
[2,1-α]isoquinoline)[163]. However, this compound was not optimal for 5-HTT 
quantification, given its high non-specific binding and slow brain uptake[135]. 
 
Subsequently, a number of radioligands have been derived from the diaryl sulfide 
series. In a comparison of the properties of four of these and the reference 5-HTT agent 
[
11
C](+)McN5652, [
11
C]DASB was singled out for its faster kinetic uptake, enabling 
shorter scanning times[164]. The position of [
11
C]DASB as the leading 5-HTT PET 
radioligand has thereafter been challenged by a relative newcomer in the diaryl sulfide 
family, [
11
C]MADAM[165]. 
 
1.5.1.1 [11C]MADAM 
Our research group has developed the high affinity 5-HTT radioligand [
11
C]MADAM, 
a close analogue to [
11
C]DASB[166]. [
11
C]MADAM binds selectively and reversibly to 
5-HTT[165].  
 
The rank order of binding potentials in different brain regions in humans has been 
shown to be in accordance with post mortem 5-HTT binding[129, 130, 133, 167]. 
[
11
C]MADAM binding in the cerebellum was sufficiently low to allow for simplified 
quantitative methods, with cerebellum as reference region[133].  
 
Good to excellent reproducibility has been demonstrated in test-retest measurements 
with [
11
C]MADAM[168]. 5-HTT occupancy has been shown with the SSRI citalopram 
and its S-enantiomer escitalopram[169]. 
 
1.5.2 Imaging the 5-HT1B receptor 
The development of 5-HT1B receptor radioligands has been delayed by the 
misinterpretation that this receptor existed only in rodents. Relatively recently two 5-
HT1B receptor antagonists have emerged for imaging of 5-HT1B receptors: [
11
C]P943 
(R-1-[4-(2-methoxy-isopropyl)-3-[2-(4-methyl-piperazin-1-yl)benzyl]-pyrrolidin-2-
one)  and [
11
C]AZ10419369 (5-methyl-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-
chromene-2-carboxylic acid(4-morhpholin-4-yl-phenyl)-amide)(figure 4). Both 
[
11
C]AZ10419369 and [
11
C]P943 have high affinity for 5-HT1B receptors (KD=0.4 and 
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KD=1.2 nM respectively)[6]. Sensitivity to pharmacologically enhanced levels of 
endogenous serotonin has been demonstrated in non-human primates for the above 5-
HT1B receptor antagonists[170-173], although no significant displacement of 
[
11
C]AZ10419369 binding occurred after a single dose of SSRI in humans[148].   
 
 
 
Figure 4. Structural formulas for 5-HT1B receptor radioligands 
 
1.5.2.1  [11C]AZ10419369 
The development of the 5-HT1B receptor selective radioligand [
11
C]AZ10419369 was 
initially a joint venture, involving Astra Zeneca Pharmaceuticals and the PET group at 
Karolinska Institutet[174]. In vivo studies have demonstrated rapid brain uptake of 
[
11
C]AZ10419369 [147] and no significant amounts of metabolites entering the CNS 
after injection[146]. Reduced [
11
C]AZ10419369 binding after pretreatment with a 5-
HT1B receptor selective antagonist has confirmed specific 5-HT1B receptor 
binding[147]. 
 
The [
11
C]AZ10419369 radioactivity distribution has been in agreement with know 5-
HT1B receptor densities[145-147]. The radioactivity was distinctly the lowest in 
cerebellum[146], a region practically devoid of 5-HT1B receptors[145]. Binding 
potentials calculated with reference tissue models, with cerebellum as reference region, 
correlated with those obtained with kinetic compartment analysis[146]. 
 
 The test-retest properties of [
11
C]AZ10419369 binding are high in cortical regions and 
satisfactory in subcortical regions[175]. 5-HT1B receptor occupancy has been 
demonstrated with PET and [
11
C]AZ10419369[176].  
 
1.6 PET STUDIES OF MAJOR DEPRESSION 
In the early days of PET, neuroreceptor imaging of major depression was hampered by 
a lack of suitable radioligands[177]. The earliest PET literature on depression consists 
mainly of functional studies. Early on, the limbic system and in particular the anterior 
cingulate cortex was implicated in the postulated neurocircuitry of depression[178].  
 
Functional PET studies have turned the subgenual prefrontal cortex (SGPFC), a 
subdivision of the anterior cingulate cortex, ventral to the genu of corpus callosum 
(Brodmann area 25), into a prime region of interest in depressive disorder[179]. In a 
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pioneering PET study Drevets et al. found 7.7% lower blood flow in the subgenual 
prefrontal cortex in depressives relative to controls[180]. This could partially be 
explained by lower grey matter volume in the subgenual prefrontal cortex in the 
depressed subjects, as measured with MRI. The lower blood flow and metabolism in 
SGPFC is a replicated finding in major depressive disorder (MDD)[181-183]. The 
reduced SGPFC volume in MDD has been corroborated in a meta-analysis of 
volumetric studies[184]. It has been suggested that, when correcting for the consequent 
partial volume effects, metabolism in the SGPFC might actually be increased in 
depressed subjects[179]. The main argument put forward is the decreased blood flow in 
the SGPFC seen during improvement associated with deep brain stimulation of the 
SGPFC[185].  
 
During the last two decades radioligand development has boomed. At present, there are 
several monoaminergic targets available for neuroreceptor imaging[186]. The bulk of 
molecular imaging studies of MDD are dedicated to targets in the serotonin 
system[186].  
 
The possibly most replicated finding in receptor imaging of depression is lower 5-HT1A 
receptor binding in the raphe nuclei and limbic and cortical regions in subjects with 
MDD compared with controls[187-189]. This is in agreement with the reduced 5-HT1A 
receptor mRNA concentrations found post mortem in the hippocampus in suicide 
victims with a history of depression[190]. The reduced 5-HT1A receptor levels did not 
change with antidepressant treatment[187] and persisted after recovery from 
depression[188], implying that the lower 5-HT1A receptor binding might reflect a 
vulnerability trait for depression, rather than the depressive state in itself. However, 
elevated 5-HT1A receptor binding has also been reported in depression[191]. Shreshta et 
al. hypothesized that the reduced 5-HT1A receptor BPND in different serotonergic 
projection areas might have been an artefact, caused by differing 5-HT1A receptor 
binding in the grey matter of the reference region cerebellum. The authors instead 
advocated the use of cerebellar white matter for reference[192]. Still, lower 5-HT1A 
receptor BPND in depression has also been demonstrated with cerebellar white matter as 
reference region[193].  
 
Imaging of the serotonin transporter in MDD has provided partially inconsistent 
findings, with higher, lower or no difference in 5-HTT binding when comparing 
depressed subjects with controls[186, 194]. Two intriguing findings imply that 
depression might primarily correspond to increased 5-HTT binding. Firstly, Cannon et 
al. demonstrated a correlation between increased 5-HTT binding in the thalamus and 
depression severity[195]. Secondly, [
11
C]DASB binding in serotonergic projection 
areas was strongly associated with the severity of negativistic dysfunctional 
attitudes[196]. However, either decreases or no change in serotonin transporter binding 
has been found in the cerebral cortex in depressed subjects post mortem[197].  
 
The data on 5-HT2A receptors in depression do not show any clear general trend[186]. 
Medications might have confounded some of the results, since reduced 5-HT2A receptor 
binding has been observed after SSRI treatment, at least in young subjects[198]. 
Increased 5-HT2A receptor binding has been reported in a subgroup of depressed 
subjects with extremely dysfunctional attitudes[199]. Bhagwagar and co-workers 
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replicated a correlation between dysfunctional attitudes score and 5-HT2A binding 
potential, albeit in patients recovered from depression[200]. 
 
As yet, there is only one case-control PET study of 5-HT1B receptor binding in MDD, 
reporting lower [
11
C]P943 binding in the ventral striatum in depressed subjects 
compared with controls[158]. The intracellular protein p11 is important for 5-HT1B 
receptor function, and has been implicated in depressive behaviour in p11 knockout 
mice[201]. In this elegant study by Svenningsson et al., lower p11 mRNA and protein 
in the ACC in depressed subjects was also reported[201]. 
 
The clinical heterogeneity inherent within the depressive syndrome[30] poses a 
challenge for the research on the pathophysiology of  major depression. One way to 
increase the phenotypic homogeneity in MDD is to study patients with recurrent major 
depressive disorder, a condition that is likely more hereditary than are solitary 
depressive episodes[10]. In a recent position paper, Savitz and Drevets summarized the 
current state of knowledge on neuroimaging for depression, concluding that although 
there are promising results, there are currently no brain imaging biomarkers that can be 
used for diagnosing depression or predicting antidepressant treatment response[202]. 
 
 
1.7 PET STUDIES OF ANTIDEPRESSANTS 
PET studies of the effect of antidepressants have mainly served two purposes: in vivo 
confirmation of in vitro and ex vivo derived hypotheses of mechanisms of action and 
clinical dose finding. The pioneering PET studies of D2 dopamine receptor occupancy 
in relation to antipsychotic effect and extrapyramidal side effects have constituted a 
model for clinical occupancy studies[203-205]. Based on the results it was 
hypothesized that a therapeutic window of 70-80 % D2 dopamine receptor occupancy 
would be optimal for antipsychotic treatment with classical neuroleptics[5]. With the 
advent of selective serotonin reuptake inhibitors, the serotonin transporter became a 
rational target for occupancy studies with antidepressants[194]. In the 5-HTT 
occupancy studies so far, attempts have been made to relate occupancy to clinical effect 
but not to side effects, possibly since the serotonergic side effects are not as distinctly 
dose-responsive as the extrapyramidal symptoms that might occur with neuroleptic 
treatment.   
 
A [
11
C]DASB PET study quickly confirmed 5-HTT occupancy in the living human 
brain with SSRI treatment[206]. Suhara et al. reported 5-HTT occupancy with a 
tricyclic antidepressant as well as with an SSRI, with surprisingly high 5-HTT 
occupancies at low doses[62]. Meyer and co-workers have conducted the largest PET 
study of 5-HTT occupancy so far, with five different SSRIs and 82 subjects[61]. No 
association between 5-HTT occupancy and depression symptom ratings was found. 
Despite this lack of correlation between 5-HTT occupancy and clinical effect a 
threshold of 80 % 5-HTT occupancy was suggested for therapeutic effect, based on the 
striatal 5-HTT occupancies seen with SSRI treatment in the clinical dosing range. This 
postulated minimum of 5-HTT occupancy has been applied in a dose-finding study for 
the SNRI duloxetine[207].   
 
 26 
 
Most PET studies on SSRI have indeed demonstrated 5-HTT occupancies of 80 % or 
more[194]. Already 2003, Suhara et al. noted that further dose escalation beyond this 
level would have a minimal effect on 5-HTT blockade[62]. With high SSRI doses 85 % 
striatal 5-HTT occupancy has been reported[208]. Lower 5-HTT occupancies, around 
70 %, have been demonstrated after single doses of SSRIs[169, 209]. 
 
With the development of (S,S)-[
18
F]Me-NER-D2, the norepinephrine transporter (NET) 
can be visualized in the human brain in vivo[210], enabling studies of the other main 
antidepressant pathway proposed – inhibition of noradrenaline reuptake[211] . NET 
occupancy after nortriptyline administration was first demonstrated in healthy 
volunteers[212] and subsequently in depressed patients responding to nortriptyline 
treatment[213]. Based on data from this clinical PET study, the recommended NET 
occupancy threshold for antidepressant treatment with nortriptyline was 50%[213]. 
 
One of the most intriguing new findings in the PET studies of compounds with 
antidepressive properties is a recent [
11
C]AZ10419369 and [
11
C]DASB PET study of 
ketamine effect in non-human primates, with potential bearing also on imaging studies 
of the serotonin system in MDD. Yamanaka and co-workers reported a significant 
increase in 5-HT1B receptor binding in the nucleus accumbens and ventral pallidum, as 
well as a significantly reduced 5-HTT binding in these brain regions upon ketamine 
administration[214].   
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2 AIMS 
The overall objective of this thesis was to contribute to the PET studies of the serotonin 
system in major depression and its treatment. The specific aims were: 
 
1. To confirm 5-HTT occupancy as a shared mechanism of action in the living 
brain for first and second generation antidepressants, TCAs and SSRIs, in 
patients who previously had responded to treatment.  
2. To examine the effect of cognitive behavioural therapy for depression on 5-
HT1B receptor binding. 
3. To compare 5-HT1B receptor binding in unmedicated patients with an ongoing 
moderate depressive episode within recurrent major depressive disorder with 
age- and sex matched controls. 
4. To assess the sensitivity of [11C]AZ10419369 binding to basal serotonin levels, 
by correlating BPND with CSF concentrations of serotonin and its metabolite 5-
HIAA in healthy volunteers.  
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3 MATERIALS AND METHODS 
 
3.1 ETHICS 
We adhered strictly to the Declaration of Helsinki in all studies, which emphasizes that 
no medical research on humans should be conducted without informed consent. All 
studies were approved by the relevant ethical review boards and by the Radiation 
Safety Committee at the Karolinska University Hospital. No experimental procedures 
were performed before the subjects had given informed consent.  
 
The patients in paper II got treatment with internet-based CBT through participation in 
the study. These patients were informed that they could get treatment even without 
being enrolled in the study. The excluded patients that were eligible for internet-CBT 
were offered this treatment. Otherwise the subjects did not receive any personal gains 
from participating in the studies, apart from a small economical compensation for their 
efforts. 
 
Basically, the risk from the exposure to a low dose of radiation for the subjects was to 
be weighed against the increase in knowledge of the serotonin system in relation to 
depression and its treatment gained through the studies. In paper IV, there was also a 
risk for post lumbar puncture headache. According to our judgement, approved by 
ethical review boards, the increased knowledge about the pathophysiology of 
depression and the mechanisms of actions of its treatment obtained through these 
studies outweighed the above risks.  
 
3.2 SUBJECTS 
The studies in this thesis used only human participants. The examinations were 
approved by the relevant ethical review boards and by the Radiation Safety Committee 
at the Karolinska University Hospital. The subjects were physically essentially healthy, 
according to medical history, physical examination, lab tests and magnetic resonance 
imaging (MRI) of the brain. 
 
3.2.1 Patients 
In paper I, responders to pharmacological treatment of depression in monotherapy, with 
any of seven different antidepressants at different doses, were recruited from 
psychiatric outpatient clinics or primary health care centres. Twenty patients were 
examined: 6 males and 14 females, aged 22-59 years. 
 
In papers II-III ten patients with an on-going and untreated major depressive episode of 
moderate severity within recurrent major depressive disorder were included. Patients 
with bipolar disorder, on-going psychopharmacological treatment (wash out-period>1 
month), organic brain disorder, drug or alcohol abuse, and suicidal patients were 
excluded. Six males and four females, aged 24-68 years, were examined. 
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3.2.2 Controls 
The controls were deemed healthy according to the above medical assessment. In 
addition, the controls were mentally healthy, according to medical history and a 
structured clinical interview. The controls for paper II-III were matched to the patients 
by age (±3 years) and sex. Seventeen controls were examined, 8 males and 9 females, 
aged 20-69 years. 
 
3.3 POSITRON EMISSION TOMOGRAPHY AND MAGNETIC 
RESONANCE IMAGING 
Two different PET systems were used in this thesis: ECAT EXACT HR 47 (Siemens, 
Berlin and Munich, Germany), which was run in the three-dimensional mode[215] 
(paper I) or ECAT HRRT (High Resolution Research Tomograph, Siemens Molecular 
Imaging) (papers II-IV). The inplane and axial resolution of the ECAT EXACT HR 47 
was ~3.8 and 4.0 mm, respectively, FWHM. The spatial resolution of the HRRT 
system was approximately 1.5 mm in the centre and 2.4 mm at 10 cm off-centre 
FWHM with the current protocol[216].  
 
Brain radioactivity was measured in a list mode fashion during 93 (papers I-III) or 63 
(paper IV) minutes. Scatter correction was performed as described in the literature[215, 
216]. Emission data were attenuation-corrected to compensate for the loss of signal 
through tissue propagation, as estimated by the preceding transmission scan. The 
resulting images were reconstructed in a series of time frames either with filtered back 
projection with a 2 mm FWHM Hann filter (ECAT EXACT HR 47) or with the three-
dimensional ordinary Poisson-ordered subset expectation maximization algorithm (3D-
OP-OSEM) (HRRT). 3D-OP-OSEM has been optimized to 10 iterations and 16 subsets 
for the HRRT. 
 
Movement correction algorithms were applied in papers II-IV. For most subjects, each 
minute block of frames was realigned to a summation of the first four time 
frames[217]. For some, subjects the head movements during PET exceeded the limits 
of this protocol. Hence the PET images were reconstructed manually using frame- 
specific attenuation-data.  
 
MRI was performed before PET with either a 1.5 Tesla system or a 3 Tesla system. The 
MRI protocol included a T2-weighted sequence to rule out pathology and a T1-
weighted 3-dimensional sequence for optimal visualization of anatomy and for 
coregistration with PET images. The T1 sequence was a 3D FSPGR BRAVO protocol 
in the axial plane with the following settings: repetition time 8.132 ms, echo time 
3.18 ms, flip angle 12°, field of view 256 mm, matrix 256 × 256×176, slice thickness 
1.0 mm, number of excitations = 1. 
 
The MR images were adjusted to position the anterior-posterior commissural (AC-PC) 
line in the horizontal plane and the interhemispheric plane orthogonal to the AC-PC 
plane. The MR images were then resampled and cropped to generate a 256X256X141 
matrix with 1 mm
2
 pixels. This matrix was coregistered to the PET images with rigid 
body transformation using SPM2 or SPM5[218]. 
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In paper III depressed patients were compared with controls. Lower volumes in the 
subgenual cingulate cortex in patients with mood disorders is a replicated finding[184]. 
The partial volume effect increases with smaller volumes, when a larger percentage of 
the radioactivity spills out of the ROI. Therefore the PET files in paper III were 
corrected for partial volume effects with the method developed by Meltzer et al.[219].   
 
3.4 EXAMINATION PROCEDURE  
Before each PET examination a plaster helmet was made for each subject according to 
an established procedure[220], to fit into a head fixation system, for reproducible 
position alignment and minimization of head movements during PET. [
11
C]MADAM 
(paper I) or [
11
C]AZ10419369 (papers II-IV) was synthesized as previously 
described[147, 166]. The subject was placed recumbent with his or her head in the PET 
system. A sterile physiological phosphate buffer (pH=7.4) solution containing the 
radioligand was prepared for injection with either 300 MBq (paper I) or 400 MBq 
(papers II-IV) and diluted with saline to a volume of 10 ml. The radioligand solution 
was then injected as a bolus into an antecubital vein, which was flushed with 10 ml 
saline immediately thereafter. Brain radioactivity was measured as described in 3.3.  
   
3.5 REGIONS OF INTEREST 
In papers I-III regions of interest (ROIs) were drawn manually on MR images using the 
Human Brain Atlas software[221]. In paper I ROIs for putamen and cerebellum were 
delineated on five consecutive horizontal sections. In papers II-III ROIs were defined 
for orbitofrontal cortex, anterior cingulate cortex, subgenual prefrontal cortex, 
amygdala, hippocampus, ventral striatum, dorsal brain stem and cerebellum. The ROIs 
in papers II-III were delineated as previously described[146], except for the ROI for the 
dorsal brain stem, which was drawn on 5 consecutive horizontal sections of the dorsal 
half of the brain stem, ranging from the lower limit of the inferior colliculi to the 
isthmus.  
 
In paper IV ROIs for the occipital cortex and the caudate nucleus were defined with the 
Automated Anatomical Labeling (AAL) template[222]. 
 
3.6 QUANTIFICATION OF RADIOLIGAND BINDING 
Within each defined region the accumulated radioactivity was measured in each time-
frame. The radioactivity represented three fractions of radioligand: free, non-
specifically bound and specifically bound. With kinetic analyses of regional time-
activity curves the measured radioactivity can be transformed into an estimation of 
radioligand binding. Since the studies reported in papers I-III were clinical studies and 
since reference tissue modelling has been found suitable for the applied 
radioligands[133, 146], invasive measurements of arterial input were avoided in this 
thesis.  
 
The binding capacity of the radioligand depends on the density of the target protein, 
Bmax, and the affinity of the radioligand for the target protein, 1/KD. These two factors 
cannot be distinguished from each other by in vivo measurements with tracer 
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methodology in human subjects, as in PET measurements. Instead the binding 
potential, BP, has been introduced as a concept to estimate target protein densities[223]. 
BP is the product of target protein density, Bmax, and the affinity of the radioligand, 
1/KD:  
  
   
    
  
 
   
 
The BP model assumes that the radioligand is homogenously distributed over the 
examined compartments.  
 
When a reference tissue model is used, the resulting binding potential is referred to as 
non-displaceable binding potential (BPND)[224]. The binding potential is then 
calculated by comparing the radioactivity in the ROI with that of the reference region, 
which ideally should be devoid of the target protein, and therefore of specific binding to 
displace. The cerebellum was used as reference region in this thesis, since it has 
negligible densities of 5-HTT and 5-HT1B receptors[129-132, 145]. Reference tissue 
modelling carry an inherent risk, since the results in the ROIs are calculated relative to 
data in the reference region. A difference in BPND between examined groups could thus 
depend on both differing radioactivity in the ROI, but also on differences in the 
reference region. Global differences in BPND should thus be treated with caution in 
studies of pathophysiology.  
 
3.6.1 The simplified reference tissue model 
The simplified reference tissue model (SRTM) was used to calculate BPND in papers I, 
III and IV[225]. The radioactivity in each ROI was compared with the radioactivity in 
the cerebellum, which served as reference region, providing an approximation of the 
radioactivity for non-specifically bound and free radioligand. The concentration of non-
displaceable radioligand was assumed to be the same in the ROIs as in the cerebellum.   
 
3.6.2 The linear graphics analysis 
In studies II-III [
11
C]AZ10419369 BPND was also calculated with the non-invasive 
Logan plot[226]. The linear graphic analysis for reversible ligand binding to target 
proteins was developed by Logan et al.[227] and initially required an arterial input 
function (invasive Logan plot).  
 
The slope of the plot when the linear phase has been reached corresponds to the plasma 
volume plus the total volume of distribution of the radioligand. The volume of 
distribution is defined as the amount of plasma needed to correspond to the amount of 
radioligand in 1 cm
3
 tissue in the brain[224].  
 
Similarly, the slope of the linear part of the non-invasive Logan plot can provide the 
distribution volume ratio (DVR), from which BPND can be derived as follows:     
 
                           (2) 
(1) 
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VT is the volume of distribution in the tissue region of interest and VND the volume of 
distribution in the reference region, here the cerebellum. 
 
3.6.3 Wavelet-aided parametric imaging 
In papers II and III 7 or 8 brain ROIs were analyzed. The dorsal brain stem ROI was 
delineated to encompass the median raphe nucleus, hypothesized to be of importance in 
major depression and its treatment[111, 228]. The 5-HT1B receptor mRNA expression 
in the median raphe is relatively low[229]. Therefore the signal-to-noise ratio was 
expected to be lower in this region compared to the other examined ROIs. To 
compensate for this a Wavelet-Aided Parametric Imaging approach (WAPI) was used 
to filter out noise. The wavelet transform separated signal components with lower 
frequency from noise with higher frequency[230]. The number of iterations (depth of 
decomposition) and filter kernel have previously been optimized to 3 and 16, 
respectively[231]. 3-D stationary WAPI (S-WAPI) is translation-invariant and has been 
validated for in vivo-measurements in the human brain[232]. S-WAPI was used in 
papers II-III. Since WAPI is computationally demanding, the relatively economical 
linear graphics analysis described in 3.6.2 was applied in the calculation of BPND 
values.  
   
3.6.4 Occupancy and Ki dose 
PET is an excellent method for determining drug receptor occupancy in vivo[233], and 
this technique has been used to determine 5-HTT occupancy in a dose-finding study for 
the antidepressant duloxetine[207]. Occupancy is here defined as the percentage of 
target proteins that are occupied by drug binding. With two PET examinations, one 
with drug treatment and one without, occupancy can be calculated with the given 
formula: 
 
             
           
           
        (3) 
 
Equation (3) was used to determine 5-HTT occupancy in paper I. BPtreatment was the 
BPND in the putamen in patients with antidepressant treatment at steady state. This was 
compared with the average BPND in the putamen of an untreated reference group, 
BPreference. 
 
The relationship between occupancy and dose can be described by a curvilinear 
function given by the following equation (4): 
 
   
       
        
    (4) 
 
where B is the concentration of ligand bound to 5-HTT, Bmax the concentration of 
available 5-HTT, F the concentration of unbound ligand and Ki app the apparent 
inhibition constant.  
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In paper I the inhibition constant was referred to as Ki dose, since the calculations were 
based on dose, for estimation of the 5-HTT affinity of the drug, based on the occupancy 
achieved with the prescribed dose. If a linear relationship between antidepressant dose 
and drug concentration in the brain is assumed, F may be substituted with dose. 
Accordingly, equation (4) may be rewritten as follows: 
 
           
           
           
   (5) 
 
 
 
where occmax is the maximal occupancy (here assumed to be 100%) and dose 
constitutes the daily dose in mg of the drug.  
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4 RESULTS AND COMMENTS 
4.1 STUDY I 
The aim of this study was to compare serotonin transporter occupancy in responders 
to seven different antidepressants to see to which extent serotonin reuptake inhibition 
is a shared mechanism of action. Patients with different doses of four SSRIs, 
citalopram, fluoxetine, sertraline, and venlafaxine, where compared with patients 
treated with two first-generation antidepressants, the TCAs amitriptyline and 
clomipramine. Mirtazapine was included as a 5-HTT “dummy.” Twenty patients on 
monotherapy were recruited.  
 
For all antidepressants but mirtazapine [
11
C]MADAM BPND in the putamen was 
lower in the patients compared to the reference group, figure 5. Mirtazapine did not 
occupy the serotonin transporter. The mean 5-HTT occupancy for the SSRIs and the 
TCAs was 67%, range 28-86 %, figure 6. The occupancy was lower for the TCAs 
than for the SSRIs, albeit not significantly so (mean 61 % versus 70 %, median 69 % 
versus 73 %, Independent Samples Kruskal Wallis Test: sig = 0.165). The doses of 
amitiptyline were on the lower end of the therapeutic range.    
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Figure 5. Examples of summated PET images (frame 6-20) of an untreated reference 
subject (top left), of subjects treated with an SSRI (citalopram, top right), a TCA 
(clomipramine, bottom left) and mirtazapine (bottom right). 
 
 
Figure 6. Histogram illustrating the relationship between drug, daily dose, and 5-
HTT occupancy. 
 
a
 Venlafaxine is sometimes also referred to as a serotonin norepinephrine reuptake 
inhibitor (SNRI), due to its affinity in vitro for both the norepinephrine transporter 
(NET) and the 5-HTT.  
 
The drug affinities correlated with the corresponding recommended clinical dose 
(Spearmans rho = 0.93, p < 0.05; table 1[234]), which provides further support for 5-
HTT occupancy as a mode of action in the treatment of depression.  
 
The average 5-HTT occupancy was significantly lower than the 80 % suggested as 
important for antidepressant effect[61]. Since we recruited responders to 
antidepressant treatment no baseline data were available. The 5-HTT BPND in the 
treated patients were instead compared with those of a male reference group. 14 of 
the patients were female. Gender differences in [
11
C]MADAM binding has previously 
been reported, with lower BPND in females than in males[235]. Furthermore, the mean 
age of the patients, 40 years, was 13 years higher than that of the reference group. 
Age related decline in serotonin transporter binding has been found in healthy male 
subjects[236]. The mismatch of age and gender between the patients and the 
reference group could thus possibly have resulted in an overestimation of 5-HTT 
occupancy. 
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Table 1. The calculated in vivo affinity for 5-HTT and recommended dose for each 
drug. The Ki dose is the median dose associated with 50% occupancy. 2Ki dose is 
associated with 67% occupancy. 
    
            
 
 
 
 
 
 
 
 
 
 
4.2 STUDY II 
The purpose of this study was to examine the effect of cognitive behavioural therapy 
(CBT) on 5-HT1B receptor binding. Ten patients with an untreated depressive episode 
within recurrent major depressive disorder were included and examined with PET and 
[
11
C]AZ10419369 before initiation of treatment. CBT was delivered through an internet 
platform, with weekly mail contact with a trained psychologist. A second PET 
measurement with the same radioligand was performed after treatment.  
 
All patients responded to treatment with a mean reduction of 18.6 points on the 
MADRS score (p<0.001) and average Clinical Global Impression-Severity scores 
going down from 3.7 to 1.5 (p<0.001). The assessed MADRS score correlated with 
selfratings before and after CBT (ρ=0.65, p<0.05 and ρ=0.71, p<0.05, respectively).  
 
The [
11
C]AZ10419369 BPND was reduced by 33 % (p=0.001) in the Dorsal Brain Stem 
(DBS) after CBT(table 2, figure 7). There was a trend towards reduced binding post-
treatment also in the hippocampus (p=0.09). There were no other significant differences 
in [
11
C]AZ10419369 binding in the brain with treatment.    
 
Similar results were obtained from the voxel-based comparisons of [
11
C]AZ10419369 
BPND at PET1 and PET2. There was only one cluster  in the brain with a significant 
change in BPND (p=0.01 corrected for multiple comparisons), a cluster of 190 voxels 
(1520 mm
3
) with significant decrease in BPND, whose distribution and size resembles 
that of the ROI for the DBS (1309 mm
3
). This cluster resided primarily in the dorsal 
brain stem, although parts of it spilled over into surrounding structures. There was a 
significant correlation between BPND change (%) in the voxel cluster and the DBS ROI 
(Spearman´s ρ =0.74; p<0.05).  
 
 
Substance   Ki dose (mg) 2 Ki dose (mg) Recommended  
daily dose (mg)
 
Fluoxetine   14 28 20 
Citalopram   21 42 20 
Sertraline   22 44 50 
Clomipramine   28 56 75 
Amitriptyline   59 118 75 
Venlafaxine   66 132 75 
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Figure 7. Midline sagittal view of the hemisphere (top) and the brainstem (bottom) of 
average files (average of summation images of eight subjects), from PET1 (left) and 
PET2 (right). The red arrows indicate the median raphe nuclei. 
 
There was a strong negative correlation between age and [
11
C]AZ10419369 BPND in 
DBS, both  at PET1 and PET2 (ρ=-0.90; p<0.001 and ρ=-0.89; p<0.001). No 
significant correlation was found between [
11
C]AZ10419369 BPND in the DBS and 
MADRS or CGI at PET1 or PET2, when corrected for age (partial correlation, ρ=-0.41, 
p=0.27 or ρ=-0.25, p=0.51).  No significant correlation between Δ[11C]AZ10419369 
BPND and ΔMADRS was found when introducing MADRS as a regressor in the voxel 
based analysis (p > 0.05; cluster level, Gaussian random-field theory corrected). 
 
The DBS ROI was drawn to include the median raphe nuclei, which cannot be 
distinguished on the MR image. The overinclusive DBS inevitably contains a portion of 
white matter, which attenuates the signal from the ROI, leading to an underestimation 
of Bmax. The actual difference in binding in the raphe nuclei between first and second 
PET might thus be more pronounced than reported here.  
 
[
11
C]AZ10419369 binds selectively to the 5-HT1B receptor and has also been shown to 
be sensitive to pharmacologically induced serotonin release. The reduced binding in the 
DBS could either reflect lower 5-HT1B receptor densities or increased serotonin levels. 
Since 5-HT1B receptors inhibit serotonin release, the reduced [
11
C]AZ10419369 BPND 
would result in a stimulation of the serotonin system in both cases. Given the lack of 
correlation between [
11
C]AZ10419369 binding and serotonin in the CSF (reported in 
study IV) we find reduced 5-HT1B receptor levels the more likely explanation.   
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Table 2. [
11
C]AZ10419369 BPND for different ROIs  
 
 
 
OFC = Orbitofrontal Cortex 
VST = Ventral Striatum 
DBS = Dorsal Brain Stem 
ACC= Anterior Cingulate Cortex 
SGPFC = Subgenual Prefrontal Cortex 
Degrees of freedom for all ROIs: 9 
a= p=0.007 with Bonferroni correction for multiple comparisons 
 
4.3 STUDY III 
The aim of this study was to compare 5-HT1B receptor levels in the brain in ten patients 
with an ongoing and untreated depressive episode within recurrent major depressive 
disorder with age and sex-matched controls. PET and the 5-HT1B receptor selective 
radioligand [
11
C]AZ10419369 was used. The PET data from the depressed patients 
were acquired from baseline PET in study II. 
 
The [
11
C]AZ10419369 binding was 25% lower in the anterior cingulate cortex in 
depressed patients compared with controls (p=0.003) (table 3). A significant difference 
was also found in the subgenual prefrontal cortex, corresponding to Brodmann area 25, 
with 20 % lower BPND for the patients than for the controls (p=0.044). The largest 
difference was found in the hippocampus ROI, where the average BPND was 45 % 
lower in the depressed subjects compared with the controls (p=0.029).  For other 
regions in the brain, including the ventral striatum and pallidum, there were no 
significant differences in BPND between patients and controls (table 3). The ROI 
volumes in the patients did not differ significantly from those of the controls.  
 
The lower [
11
C]AZ10419369 binding potentials in the depressed patients were found in 
two different parts of the cingulate cortex, considered important in the neurocircuitry of 
depression[178, 237]. The subgenual prefrontal cortex, Brodmann area 25, closely 
corresponds to the target region for deep brain stimulation for treatment- 
resistant depression[185]. The [
11
C]AZ10419369 BPND in the anterior cingulate cortex 
and subgenual prefrontal cortex did not change with psychotherapy, despite treatment 
response. With no treatment effect on radioligand binding in ACC or SGPFC, the 
reported decreases in depression are most likely trait-dependent, reflecting either 
vulnerabilities for depression or a consequence of the disorder. Based on the lack of 
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correlation between [
11
C]AZ10419369 binding and CSF serotonin described in study 
IV the lower radioligand binding in ACC and SGPFC in depression likely reflects 
lower levels of 5-HT1B-receptors in these brain regions. We could not replicate the 
previously reported difference in 5-HT1B receptor binding in the ventral striatum or 
pallidum between depressed subjects and controls [158].       
 
Table 3 [
11
C]AZ10419369 binding results  
 
ROI Controls BPND±SD Patients BPND±SD  p 
Orbitofrontal cortex 1.49±0.15 1.27±0.37  0,07 
ACC 1.38±0.22 1.10±0.22  0,003** 
SGPFC  1.22±0.17 1.02±0.21  0,044* 
Ventral striatum 1.98±0.34 1.70±0.45  0,242 
Pallidum 3.33±0.56 3.04±0.66  0,422 
Amygdala 1.06±0.21 0.96±0.38  0,486 
Hippocampus 0.48±0.12 0.33±0.13  0,029* 
Dorsal brain stem 0.55±0.28 0.70±0.28  0,087 
 
OC= Occipital Cortex, ACC=Anterior Cingulate Cortex, SGPFC=Subgenual Prefrontal 
Cortex. SD=Standard Deviation. 
 
 
4.4 STUDY IV 
The purpose of this study was to assess the serotonin sensitivity level for the 
radioligand [
11
C]AZ10419369 by parallel measurements of serotonin and its metabolite 
5-HIAA in the cerebrospinal fluid (CSF). Twelve subjects underwent PET and within a 
month lumbar puncture between L3/L4, where 5 ml of cerebrospinal fluid was 
collected. The mean serotonin concentration in the CSF (±s.d.) was 0,58 (±0.12) ng/ml. 
In one subject 5-HIAA levels in the CSF were below the limit of detection. The 
average 5-HIAA concentration (±s.d.) for the rest of the group was 1.49 (±1.22) ng/ml.  
When the two outliers with high 5-HIAA (>3 ng/ml) were removed from the analysis, 
an obvious correlation between CSF concentrations of 5-HIAA and serotonin was 
found (figure 8, p=0.938, p<0.001). 
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Figure 8. Scatterplot depicting the relationship between serotonin and 5-HIAA in the 
CSF. 
 
There was no correlation between [
11
C]AZ10419369 BPND  in the whole brain and CSF 
concentrations of serotonin (p=0.471) and its metabolite 5-HIAA (figures 9A and 10A, 
p=0.675). Neither [
11
C]AZ10419369 binding in the occipital cortex nor in the caudate 
nucleus correlated with CSF serotonin or 5-HIAA (figures 9B-C and 10 B-C). In 
previous post mortem studies correlations between concentrations of 5-HIAA in the 
CSF and in several brain regions have been demonstrated[119]. In the same report the 
serotonin concentration in the caudate nucleus correlated with that in the CSF[119]. 
With the lack of correlation between [
11
C]AZ10419369 BPND in the whole brain, and in 
particular the caudate nucleus, and CSF serotonin and 5-HIAA the hypothesis of 
sensitivity to physiological serotonin levels could not be corroborated. 
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Figure 9B 
 
 
 
Figure 9C 
 
Figures 9A-C. Scatterplots demonstrating the relationship between [
11
C]AZ10419369 
BPND in the whole brain (A), in the caudate nucleus (B), and in the occipital cortex  (C) 
and serotonin in the CSF. WB=Whole Brain, CN=Caudate nucleus, OC=Occipital 
Cortex. 
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Figure 10A 
 
Figure 10B 
 
 
Figure 10C 
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Figures 10A-C. Scatterplots demonstrating the relationship between 5-HIAA in the 
CSF and [
11
C]AZ10419369 BPND in the whole brain (A), in the caudate nucleus (B), 
and in the occipital cortex  (C). WB=Whole Brain, CN=Caudate Nucleus, 
OC=Occipital Cortex. 
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5 SUMMARY OF FINDINGS 
5.1 ON SEROTONIN TRANSPORTER OCCUPANCY WITH 
ANTIDEPRESSANTS 
The study corroborates 5-HTT as a shared target in the living human brain for both first 
and second generation antidepressants, TCAs and SSRIs. There was no significant 
difference in 5-HTT occupancy between the 5 patients treated with TCAs and the 14 
patients on SSRI treatment. The underlying pharmacodynamics behind the superior 
antidepressant efficacy of TCAs compared with SSRIs[74] are thus likely to be sought 
elsewhere.  
 
The 5-HTT affinities of the examined antidepressants correlated with recommended 
clinical dose, further corroborating 5-HTT occupancy in the mechanism of action of 
TCAs and SSRIs. Mirtazapine did not occupy the serotonin transporter, demonstrating 
alternative modes of action.  
 
The 5-HTT occupancy with treatment was significantly lower (61-74 %, 95 % CI, 
figure 1, table 2) than the postulated 80 % for antidepressant effect with SSRIs[61]. In 
our material, remission could be maintained with SSRI treatment on average occupying 
70 % of the serotonin transporters. 
  
 
5.2 ON THE EFFECT OF COGNITIVE BEHAVIOUR THERAPY ON 
[11C]AZ10419369 BINDING 
All patients in the study responded to cognitive behavioural therapy for depression. The 
[
11
C]AZ10419369 binding in the dorsal brain stem was reduced by 33 % after the given 
treatment. There were no other significant changes in radioligand binding in the brain 
between first and second PET.  
 
Although increased serotonin levels cannot be ruled out, the reduced [
11
C]AZ10419369 
binding in the dorsal brain stem is more likely due to decreased 5-HT1B receptor 
densities. Reduced 5-HT1B receptor activity would in theory result in increased 
serotonin release, through decreased inhibition. The dorsal brain stem contains the 
raphe nuclei, from which the serotonergic neurons project. Increased activity in the 
raphe neurons after CBT could have a global impact on the serotonin system, 
corroborating the serotonin hypothesis of depression.  
 
5.3 ON [11C]AZ10419369 BINDING IN PATIENTS WITH MAJOR 
DEPRESSIVE DISORDER COMPARED WITH CONTROLS 
The patients had lower [
11
C]AZ10419369 binding in the anterior cingulate cortex and 
the subgenual prefrontal cortex, likely corresponding to lower 5-HT1B receptor 
densities. These parts of the cingulate cortex are replicated hot spots in the 
neurocircuitry of depression. The absence of change in BPND in these regions with 
effective treatment against the depressive state implies that the lower [
11
C]AZ10419369 
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binding rather corresponds to a trait in major depressive disorder. Based on the results 
of study IV the lower [
11
C]AZ10419369 BPNDs likely reflect lower 5-HT1B receptor 
densities. There were no significant differences in the other regions of interest in the 
brain. The earlier reported lower 5-HT1B receptor levels in the ventral striatum and 
striatum in depressed subjects[158] was not replicated. 
 
 
5.4 ON [11C]AZ10419369 BINDING IN RELATION TO 5-HIAA AND 
SEROTONIN IN CEREBROSPINAL FLUID 
We found no correlations between [
11
C]AZ10419369 BPND binding in the whole brain 
or the brain regions of interest, and concentrations of serotonin and 5-HIAA in the CSF. 
The hypothesis was that [
11
C]AZ10419369 is sensitive to physiological serotonin 
levels. With the lack of correlation between serotonin measurements in the CSF and 
radioligand binding, this hypothesis could not be corroborated. For low to medium 
concentrations of 5-HIAA, there was a distinct correlation with serotonin 
concentrations in the CSF, providing support for 5-HIAA as a serotonergic marker, at 
least at low to medium 5-HIAA levels. 
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6 FINAL REMARKS AND FUTURE PERSPECTIVES 
As research goes, we have ended up with more questions than we started with. In study 
I we could confirm 5-HTT occupancy with TCAs as well as with SSRIs, with no 
significant difference in the degree of occupancy. Still, with the time of onset of 
antidepressant effect, a black box remains between inhibition of serotonin reuptake and 
treatment effect with the currently available drugs for depression. Further studies of the 
contents in this black box of antidepressant effect are of vital importance for the 
development of new antidepressants.  
 
The relationship between 5-HTT occupancy and its effects is less well studied than that 
of D2 dopamine receptor occupancy, antipsychotic effect and extrapyramidal side 
effects. The main obstacle with SSRI treatment is the risk for sexual side effects, such 
as loss of libido. Dose-finding studies correlating 5-HTT occupancy with 
antidepressant effect and sexual side effects with different doses of SSRI would be of 
value for optimizing the clinical use of SSRIs. 
 
Earlier studies have shown superior efficacy with TCAs compared with SSRIs, at least 
in a subgroup of patients. The similar 5-HTT occupancies in these two groups of 
antidepressants indicate that the potential advantage in antidepressant effect of TCAs is 
mediated via additional mechanisms of action. The anticholinergic side effects of 
TCAs, together with the putative antidepressant effects of the anticholinergic drug 
scopolamine and the use of vagus nerve stimulation in the treatment of depression all 
provide a rationale for further exploration of the effects of modulating the acetylcholine 
system in depression. Finally, the lack of 5-HTT occupancy with mirtazapine illustrates 
that there are other mechanisms of action than inhibition of serotonin reuptake in the 
pharmacological treatment of depression.    
 
In study II we found a significant reduction of [
11
C]AZ10419369 binding in the dorsal 
brain stem after internet-CBT for depression. This reduction did not correlate with 
alleviated symptoms as rated with MADRS. One reason for this lack of correlation was 
the homogeneity of the patient population, in which all patients responded to the given 
treatment. Further studies with bigger samples, including non-responders, are needed to 
more adequately address the question of correlation between reduced 
[
11
C]AZ10419369 binding in the DBS and improvement from depression. Future 
studies of the brain stem in depression and its treatment would benefit from improved 
methods to visualize this challenging brain region, especially when it comes to 
delineating the raphe nuclei.  
 
The lower [
11
C]AZ10419369 binding in the anterior cingulate cortex and associated 
regions in depressed patients compared with controls reported in paper III is likely 
constituted of a difference in 5-HT1B receptor density. With the current methodology 
we cannot tell if this difference is due to fewer 5-HT1B receptor containing neurons, 
fewer synapses expressing 5-HT1B receptors or down-regulation of 5-HT1B receptors. 
To further explore this intriguing finding, studies with methods such as 
autoradiography would be needed.  
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In contrast with the previous PET study of 5-HT1B receptors in MDD there was no 
significant difference in 5-HT1B receptor binding in the ventral striatum and the 
pallidum between depressed subjects and controls. Head to head comparisons between 
the 5-HT1B receptor radioligands [
11
C]P943 and [
11
C]AZ10419369 could possibly  
elucidate the conflicting findings in the two case-control studies of 5-HT1B receptor 
binding in vivo performed in depression.  
 
There was a trend towards higher [
11
C]AZ10419369 BP in the DBS in the depressed 
patients than in the controls in study III, albeit not significant. High BP in the DBS 
would be in line with the BP reduction in the DBS after treatment with CBT. The 
patient sample in this study was small, and the risk of type II errors evident. Studies 
with larger samples or pooled analyses, such as with a meta-analysis, would increase 
the power and hence reduce this risk. 
 
Studies II and III implicate the 5-HT1B receptor as a possible target in the treatment of 
depression.  
 
Study IV addressed the sensitivity of [
11
C]AZ10419369 binding to baseline serotonin 
concentrations. No significant correlations were found between CSF concentrations of 
serotonin and 5-HIAA and [
11
C]AZ10419369 BPND in the whole brain, the caudate 
nucleus or in the occipital cortex. The serotonin concentration threshold for 
displacement of [
11
C]AZ10419369 is likely to be somewhere in between baseline 
serotonin levels in the brain and those brought about with pharmacological serotonin 
enhancement.  
 
The development of agonist tracers targeting 5-HT1B receptors would in theory yield 
radioligands more sensitive to endogenous serotonin, since they, like serotonin itself, 
only bind to receptors in the high affinity state.    
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